Biological membrane phospholipids (PL)

Biological membrane phospholipids are essential amphipathic molecules that constitute the structural foundation of all cellular membranes, forming a semi-permeable lipid bilayer (NCBI, 2023) [3]. These molecules, which include phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine, are vital for maintaining cellular compartmentalization, regulating the activity of membrane-bound proteins, and serving as precursors for signaling molecules like diacylglycerol and inositol triphosphate (Journal of Lipid Research, 2021) [5]. In a therapeutic context, membrane phospholipids are targeted by specific classes of antibiotics, such as polymyxins and daptomycin, which exploit differences between bacterial and mammalian membrane compositions to selectively disrupt microbial integrity (StatPearls, 2023) [1, 2]. Furthermore, synthetic or animal-derived phospholipids are used as replacement therapies for conditions like neonatal respiratory distress syndrome, where they function to lower alveolar surface tension and prevent lung collapse (NIH, 2022) [4]. However, the ubiquitous nature of phospholipids in human tissues presents a significant challenge for drug development, as off-target interactions can lead to severe side effects like nephrotoxicity or neurotoxicity (StatPearls, 2023) [2].

Other names

Membrane phospholipidsGlycerophospholipidsPhosphoglyceridesCell membrane lipidsPhospholipids

Drugs targeting membrane phospholipids typically act by binding to specific lipid head groups or acyl chains, leading to membrane depolarization, pore formation, or physical disruption of the lipid bilayer (StatPearls, 2023) [1, 2]. In the case of lung surfactants, exogenous phospholipids are administered to replace deficient endogenous lipids and restore normal surface tension in pulmonary alveoli (NIH, 2022) [4].